Nuvalent Inc (NUVL)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | PHARMACEUTICALS |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | James R. Porter |
| Employees: | 40 |
| Web site: | nuvalent.com |
|
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE, MA, 02142
508-446-2272
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations.
Please log in first to see chart